U-Ploid Biotechnologies launches collaborative research study with San Diego Fertility Center and Nova Genomics

SAN DIEGO, US - 24 February 2026 - U-Ploid Biotechnologies has initiated a new collaborative research study with San Diego Fertility Center (SDFC) and Nova Genomics, marking an important translational step in the company’s programme to address the biological causes of age-related infertility.

This first-of-its-kind study will investigate a novel therapeutic approach aimed at improving egg quality by reducing age-related chromosomal errors in human oocytes. The research is being conducted at San Diego Fertility Center, using donated immature oocytes of enrolled participants.

Age-related aneuploidy is a major contributor to declining fertility and IVF success rates. While advances in IVF have focused largely on improving laboratory workflows and embryo selection, there are currently no approved therapies that directly target the underlying molecular processes within the egg itself. U-Ploid’s investigational product, Lyvanta^TM, has shown promising results in pre-clinical models, demonstrating reductions in chromosomal errors in aged oocytes. This study is designed to explore whether those findings translate into human biology, while also assessing how the approach integrates within routine IVF laboratory practice.

The study will evaluate changes in oocyte aneuploidy rates following ex vivo administration of the investigational product, alongside practical measures such as oocyte survival and maturation. In parallel, the collaboration will generate operational insights to inform the design of future clinical studies and the continued development of Lyvanta^TM.

“This study represents a significant milestone for U-Ploid as we move from pre-clinical research into carefully designed human studies,” said Dr Jordan Abdi, Co-Founder and CEO of U-Ploid Biotechnologies. “Working closely with San Diego Fertility Center and Nova Genomics allows us to generate high-quality biological data while keeping feasibility, safety, and patient considerations front and centre.”

“We are pleased to collaborate on this research study, which explores a novel, biology-led approach to address age-related challenges in egg quality,” Dr. Sandy Chuan, Medical Director at San Diego Fertility Center, commented. “Thoughtfully designed research like this is essential for advancing the future of reproductive medicine.”

"Precision genetic analysis is fundamental to understanding aneuploidy in human oocytes and advancing the science of reproductive medicine," said Cynthia Hudson, Co-founder & CEO at Nova Genomics. "Nova Genomics is proud to contribute our advanced genomic capabilities and bioinformatics expertise to this groundbreaking research, which has the potential to address one of the most significant biological challenges in fertility."

‍

About U-Ploid Biotechnologies

U-Ploid Biotechnologies is an Oxford-based biotechnology company dedicated to solving one of the world’s most pressing challenges in fertility: declining egg quality. U-Ploid is developing Lyvanta™, a novel therapeutic that targets the molecular pathways of oocyte ageing. By reducing chromosomal errors by over 80% in pre-clinical mouse models, U-Ploid aims to significantly increase the probability of healthy pregnancies for women in their mid-30s and beyond.

About San Diego Fertility Center

San Diego Fertility Center is internationally recognized for excellence in reproductive medicine, in-vitro fertilization, third-party reproduction, and fertility research. With locations in Del Mar, Temecula, Mission Valley, and New York City, the center is known for strong success rates, thoughtful clinical care, and ongoing contributions to the field through research and education. The team at San Diego Fertility Center is dedicated to helping individuals and families build the families they envision, combining medical expertise with compassionate care.

About Nova Genomics

Nova Genomics is a preimplantation genetic testing (PGT) laboratory dedicated to transforming reproductive genetics by making high-precision, clinically meaningful insights accessible to every IVF journey. Founded by industry veterans Dr. Gary Harton and Cynthia Hudson, who bring over 50 years of combined expertise in reproductive genetics, Nova Genomics combines cutting-edge technology with a patient-centered approach to deliver accurate and actionable genetic testing services. The company offers comprehensive PGT services including aneuploidy screening (PGT-A), monogenic disorder testing (PGT-M), and structural rearrangement detection (PGT-SR), supported by proprietary bioinformatics pipelines that provide high-resolution analysis and enhanced quality control. Nova Genomics is committed to scientific excellence, uncompromising standards, and advancing the future of reproductive medicine through strategic partnerships and educational leadership.

‍